BRDG Park

brdg-park.com

The Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center offers leading bio-research facilities with world-class wet labs, office space for lease and on-site workforce training. Emerging scientific enterprises get just the right combination for success – interactions between top scientists and access to state-of-the-art core facilities such as technologically advanced greenhouses, growth chambers, microscopy, proteomics and tissue transformation facilities, as well as other vital resources.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

SINGLERON LAUNCHES TWO NEW INSTRUMENTS TO FURTHER STANDARDIZE SINGLE CELL ANALYSIS WORKFLOW

PRNewswire | June 19, 2023

news image

"We care for your samples, you care for science" – Singleron holds true to their slogan as reliable partner to scientists and clinicians. Developing single cell multi-omics products that can be used in research and clinical settings, the launch of two new instruments extends their current portfolio that delivers one-stop-shop solutions for the single cell sequencing workflow. Scientists and clinical researchers appreciate the prospect of portable instruments that...

Read More

Medical, Industry Outlook

REPLIMUNE AND INCYTE ENTER INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE RP1 AND INCB99280 IN PATIENTS

Businesswire | August 02, 2023

news image

Replimune Group, Inc. a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. “We are excited to enter into this collaboration with Incyte to explo...

Read More

Cell and Gene Therapy, Industrial Impact

OXFORD NANOPORE TECHNOLOGIES COLLABORATES WITH UPS HEALTHCARE

Oxford Nanopore Technologies | February 17, 2023

news image

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...

Read More

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

news image

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More
news image

Medical, Industry Outlook

SINGLERON LAUNCHES TWO NEW INSTRUMENTS TO FURTHER STANDARDIZE SINGLE CELL ANALYSIS WORKFLOW

PRNewswire | June 19, 2023

"We care for your samples, you care for science" – Singleron holds true to their slogan as reliable partner to scientists and clinicians. Developing single cell multi-omics products that can be used in research and clinical settings, the launch of two new instruments extends their current portfolio that delivers one-stop-shop solutions for the single cell sequencing workflow. Scientists and clinical researchers appreciate the prospect of portable instruments that...

Read More
news image

Medical, Industry Outlook

REPLIMUNE AND INCYTE ENTER INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE RP1 AND INCB99280 IN PATIENTS

Businesswire | August 02, 2023

Replimune Group, Inc. a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. “We are excited to enter into this collaboration with Incyte to explo...

Read More
news image

Cell and Gene Therapy, Industrial Impact

OXFORD NANOPORE TECHNOLOGIES COLLABORATES WITH UPS HEALTHCARE

Oxford Nanopore Technologies | February 17, 2023

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...

Read More
news image

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us